XTX Topco Ltd Buys 19,727 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

XTX Topco Ltd lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 97.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 40,013 shares of the biotechnology company's stock after buying an additional 19,727 shares during the period. XTX Topco Ltd owned about 0.13% of AnaptysBio worth $530,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new position in AnaptysBio in the 4th quarter valued at about $40,000. AlphaQuest LLC raised its stake in shares of AnaptysBio by 1,891.5% during the fourth quarter. AlphaQuest LLC now owns 4,461 shares of the biotechnology company's stock valued at $59,000 after acquiring an additional 4,237 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in AnaptysBio by 1,585.8% during the 4th quarter. Russell Investments Group Ltd. now owns 5,698 shares of the biotechnology company's stock worth $75,000 after purchasing an additional 5,360 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company's stock worth $85,000 after acquiring an additional 644 shares in the last quarter. Finally, Aristides Capital LLC bought a new position in shares of AnaptysBio during the 4th quarter worth approximately $168,000.

Analyst Ratings Changes

A number of research firms recently weighed in on ANAB. Wolfe Research began coverage on AnaptysBio in a research note on Tuesday, February 4th. They set an "outperform" rating and a $25.00 price target on the stock. HC Wainwright reissued a "neutral" rating and issued a $22.00 price target on shares of AnaptysBio in a report on Tuesday, March 4th. Guggenheim restated a "buy" rating on shares of AnaptysBio in a research note on Monday, March 3rd. Wells Fargo & Company upped their price target on shares of AnaptysBio from $40.00 to $51.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, JPMorgan Chase & Co. raised their price objective on shares of AnaptysBio from $36.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $33.63.

AnaptysBio Price Performance

AnaptysBio stock traded down $0.15 during mid-day trading on Friday, reaching $20.46. 76,953 shares of the company traded hands, compared to its average volume of 596,152. AnaptysBio, Inc. has a 52-week low of $12.21 and a 52-week high of $41.31. The firm has a market capitalization of $627.32 million, a price-to-earnings ratio of -3.36 and a beta of -0.09. The firm's 50 day moving average price is $17.90 and its 200 day moving average price is $19.70.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.89. The company had revenue of $43.11 million during the quarter, compared to analyst estimates of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, sell-side analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio announced that its Board of Directors has approved a share buyback plan on Monday, March 24th that allows the company to buyback $75.00 million in shares. This buyback authorization allows the biotechnology company to purchase up to 13.1% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's management believes its shares are undervalued.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.